Aquestive Therapeutics is trading 7.2% lower at $3.60 in pre-market after third-quarter revenue and EPS misses. - Revenue was $7.6 million, down 41% year over year, primarily due to Suboxone order timing; reported loss was $0.13 per share. - The company maintained full-year 2026 revenue guidance of $46–$50 million; the FDA set March 16, 2027, as Anaphylm’s PDUFA goal date. - The miss is the clearest near-term explanation, but available reporting does not establish the exact cause of the pre-market move.